Navigation Links
JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)
Date:2/27/2008

CHARLESTON, S.C., Feb. 27 /PRNewswire/ -- JSJ Pharmaceuticals is pleased to announce the introduction of its new aesthetic division, Vitivia(TM). Vitivia(TM) will focus on medically based aesthetics and utilize the clinical roots of JSJ Pharmaceuticals in the development of science-based, result-oriented products.

Vitivia(TM)'s first product introduction will be its Pro:Vitamin line. Topical vitamins have long been recognized as important tools in the anti-aging process. The benefits of most topical vitamins, however, have been limited by the inability to stabilize vitamins when exposed to air and light. For products that have attempted to address this stability issue, long lists of preservative agents have been the answer. Vitivia(TM)'s Pro:Vitamin has found an innovative solution to these challenges.

In light of the fact that today's consumers desire natural ingredients, free of chemical preservatives, fragrances, coloring, or other allergens, Vitivia(TM)'s Pro:Vitamin line combines pure concentrations of natural ingredients with the best of modern science. This formulation is then placed in individual biodegradable unit dose packaging insuring each application of Pro:Vitamin has never been exposed to light or air. As a result, the concentration of the first application is as pure and stable as the last.

"With the continued growth of medically based aesthetics, Vitivia(TM) will be an important growth factor for the future of JSJ Pharmaceuticals," stated JSJ's Chief Operating Officer, Jonathan Alba. "The introduction of the clinically proven Pro:Vitamin line will be a key part of the long-term foundation of the Vitivia(TM) division of JSJ," stated Alba.

Vitivia(TM)'s Pro:Vitamin line is available through physician offices nationally. For more information regarding the purchase or distribution of Vitivia(TM) products visit http://www.Vitivia.com or call 1-888-975-4848.

About JSJ:

JSJ Pharmaceuticals, based in Charleston, SC, is a growing specialty pharmaceutical company focused on the development and commercialization of prescriptive products to meet the diverse needs of patients suffering from a wide range of dermatological conditions. More information can be found about JSJ Pharmaceuticals at http://www.jsjpharm.com.

Media Contact:

Jon Knowles

843.965.8333 ext. 104

jknowles@jsjpharm.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE JSJ Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
2. NPS Pharmaceuticals Announces Senior Management Changes
3. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
4. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
Breaking Biology News(10 mins):